BioNTech will release 2025 financial results on March 10, 2026, and host a conference call for updates.
Quiver AI Summary
BioNTech SE will announce its financial results for the fourth quarter and full year of 2025 on March 10, 2026, and will hold a conference call and webcast at 8:00 a.m. ET to discuss these results as well as provide a corporate update. Investors and the public can register for the call to receive dial-in information, and a presentation will be available online. A replay of the webcast will be archived on the company’s website for 30 days. BioNTech is a global biopharmaceutical company focused on developing innovative immunotherapy strategies to treat cancer and other serious diseases, leveraging its mRNA technology and collaborating with various pharmaceutical partners. For more details, visit their website.
Potential Positives
- BioNTech plans to announce significant financial results for Q4 and full year 2025, indicating progress and potential growth in the company’s financial performance.
- The upcoming conference call and webcast demonstrate the company’s commitment to transparency and communication with investors and the public.
- BioNTech's diversified pipeline in oncology and infectious diseases highlights its innovative approach and potential for impactful therapeutic advancements.
- The company has established collaborations with multiple global pharmaceutical partners, which may enhance its research capabilities and market reach.
Potential Negatives
- e
FAQ
When will BioNTech announce its financial results for 2025?
BioNTech will announce its financial results on Tuesday, March 10, 2026.
What time is the BioNTech conference call scheduled?
The conference call is scheduled for 8:00 a.m. ET (1:00 p.m. CET).
How can I access the BioNTech conference call?
Participants can access the call by registering via the provided link for dial-in numbers.
Will there be a replay of the conference call available?
Yes, a replay of the conference call will be archived on BioNTech's website for 30 days.
Where can I find more information about BioNTech's corporate updates?
More information can be found on the Events & Presentations page in the Investor Relations section of BioNTech's website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BNTX Hedge Fund Activity
We have seen 137 institutional investors add shares of $BNTX stock to their portfolio, and 143 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAILLIE GIFFORD & CO removed 6,634,492 shares (-84.2%) from their portfolio in Q4 2025, for an estimated $631,603,638
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,746,944 shares (-36.1%) from their portfolio in Q4 2025, for an estimated $166,309,068
- PFIZER INC removed 1,658,361 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $157,875,967
- JANE STREET GROUP, LLC added 1,164,203 shares (+590.9%) to their portfolio in Q4 2025, for an estimated $110,832,125
- ALTRINSIC GLOBAL ADVISORS LLC removed 496,771 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $48,991,556
- D. E. SHAW & CO., INC. added 488,552 shares (+inf%) to their portfolio in Q4 2025, for an estimated $46,510,150
- FMR LLC added 480,114 shares (+8.8%) to their portfolio in Q4 2025, for an estimated $45,706,852
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BNTX Analyst Ratings
Wall Street analysts have issued reports on $BNTX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
- Morgan Stanley issued a "Overweight" rating on 10/10/2025
To track analyst ratings and price targets for $BNTX, check out Quiver Quantitative's $BNTX forecast page.
$BNTX Price Targets
Multiple analysts have issued price targets for $BNTX recently. We have seen 5 analysts offer price targets for $BNTX in the last 6 months, with a median target of $131.0.
Here are some recent targets:
- Asad Haider from Goldman Sachs set a target price of $142.0 on 01/16/2026
- Robert Burns from HC Wainwright & Co. set a target price of $140.0 on 11/10/2025
- David Dai from UBS set a target price of $117.0 on 11/06/2025
- Jessica Fye from JP Morgan set a target price of $120.0 on 10/23/2025
- Terence Flynn from Morgan Stanley set a target price of $131.0 on 10/10/2025
Full Release
MAINZ, Germany, February 24, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2025 on Tuesday, March 10, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this link . Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link .
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com . A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com .
CONTACTS
Investor Relations
Douglas Maffei, PhD
[email protected]
Media Relations
Jasmina Alatovic
[email protected]
